<DOC>
	<DOCNO>NCT02233504</DOCNO>
	<brief_summary>The purpose trial examine hematologic response rate Exjade® patient AML high risk MDS chronic iron overload blood transfusion . Deferasirox develop iron-chelating agent , unlike deferoxamine , previously develop iron chelator , deferasirox advantage oral administration .</brief_summary>
	<brief_title>Pilot Study Assess Hematologic Response Patients With Acute Myeloid Leukemia High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade ( Deferasirox )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Patients high risk MDS AML Exjade Pilot Assessing Hematologic Response AML/MDS UPCC # 40413 Newly diagnose acute myeloid leukemia , candidate intensive induction chemotherapy judgement investigator unwilling undergo intensive induction chemotherapy OR AML refractory relapse treatment nonintensive regimen , candidate allogeneic transplant time OR MDS , IPSS 1.5 great , intolerant disease progression/lack response hypomethylating agent . Age ≥ 18 year able provide independent informed consent Serum Ferritin : For enrollment study : serum ferritin ≥ 500 ng/mL screening . Samples must obtain absence concomitant infection . If transfusion schedule , draw serum ferritin PRIOR transfusion . ECOG performance status 02 . Sexually active woman must use effective method contraception , must undergo clinically document total hysterectomy and/or oophorectomy , tubal ligation postmenopausal ( define amenorrhea least 12 month ) Prior therapy intensive chemotherapy AML Prior therapy iron chelate agent within last 6 month . Serum creatinine level great 1.5x upper limit normal AST ALT level great 5x upper limit normal Current therapy AML MDS ( ≥ 4 week washout period agent use treat AML MDS prior first dose study drug require ) . Current therapy hydrea control leukocytosis . Clinical laboratory evidence active Hepatitis B Hepatitis C ( HBsAg absence HBsAb OR HCV Ab positive HCV RNA positive ALT normal range ) infection . In absence clinical suspicion active infection , laboratory test assess Hepatitis B C status require screening . Clinical history HIV positive test result ( ELISA Western blot ) . Laboratory test ass HIV status require screening . Clinical self report history drug alcohol abuse within 12 month prior enrollment ECOG Performance Status &gt; 2 Uncontrolled systemic hypertension Severe cardiac insufficiency ( NYHA III IV ) , uncontrolled and/or unstable cardiac coronary artery disease control standard medical therapy Clinical diagnosis history clinically relevant ocular toxicity relate iron chelation Systemic disease ( cardiovascular , renal , hepatic , etc . ) opinion investigator would prevent study treatment Pregnant breast feed woman Treatment systemic investigational drug within past 4 week topical investigational drug within past 7 day plan receive investigational drug participate study Other surgical medical condition might significantly alter absorption , distribution , metabolism excretion study drug History noncompliance medical regimens patient consider potentially unreliable and/or cooperative Hematopoietic stem cell transplant MDS AML . Active CNS leukemia Patients find ineligible screening procedure reason ineligibility document screen log . No data collect CRF patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>